Free Trial
NASDAQ:TWST

Twist Bioscience (TWST) Stock Price, News & Analysis

Twist Bioscience logo
$40.36
-2.82 (-6.53%)
(As of 10/31/2024 ET)

About Twist Bioscience Stock (NASDAQ:TWST)

Key Stats

Today's Range
$40.32
$42.65
50-Day Range
$36.72
$47.99
52-Week Range
$15.11
$60.90
Volume
592,823 shs
Average Volume
946,420 shs
Market Capitalization
$2.35 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$51.22
Consensus Rating
Moderate Buy

Company Overview

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Twist Bioscience Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
84th Percentile Overall Score

TWST MarketRank™: 

Twist Bioscience scored higher than 84% of companies evaluated by MarketBeat, and ranked 312th out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Twist Bioscience has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 7 buy ratings, 1 hold rating, and 1 sell rating.

  • Amount of Analyst Coverage

    Twist Bioscience has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Twist Bioscience's stock forecast and price target.
  • Earnings Growth

    Earnings for Twist Bioscience are expected to grow in the coming year, from ($3.13) to ($2.54) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Twist Bioscience is -10.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Twist Bioscience is -10.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Twist Bioscience has a P/B Ratio of 3.72. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Twist Bioscience's valuation and earnings.
  • Percentage of Shares Shorted

    15.17% of the outstanding shares of Twist Bioscience have been sold short.
  • Short Interest Ratio / Days to Cover

    Twist Bioscience has a short interest ratio ("days to cover") of 11, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Twist Bioscience has recently increased by 1.49%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Twist Bioscience does not currently pay a dividend.

  • Dividend Growth

    Twist Bioscience does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    15.17% of the outstanding shares of Twist Bioscience have been sold short.
  • Short Interest Ratio / Days to Cover

    Twist Bioscience has a short interest ratio ("days to cover") of 11, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Twist Bioscience has recently increased by 1.49%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Twist Bioscience has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for Twist Bioscience this week, compared to 4 articles on an average week.
  • Search Interest

    4 people have searched for TWST on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added Twist Bioscience to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Twist Bioscience insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,801,822.00 in company stock.

  • Percentage Held by Insiders

    Only 3.92% of the stock of Twist Bioscience is held by insiders.

  • Read more about Twist Bioscience's insider trading history.
Receive TWST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Twist Bioscience and its competitors with MarketBeat's FREE daily newsletter.

TWST Stock News Headlines

Protect Your Bank Account with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.
TWST Twist Bioscience Corporation
Leerink Partners Remains a Hold on Twist Bioscience (TWST)
See More Headlines

TWST Stock Analysis - Frequently Asked Questions

Twist Bioscience's stock was trading at $36.86 at the beginning of the year. Since then, TWST shares have increased by 9.5% and is now trading at $40.36.
View the best growth stocks for 2024 here
.

Twist Bioscience Co. (NASDAQ:TWST) released its earnings results on Friday, August, 2nd. The company reported ($1.47) earnings per share for the quarter, missing the consensus estimate of ($0.76) by $0.71. The firm's quarterly revenue was up 27.7% compared to the same quarter last year.

Twist Bioscience (TWST) raised $75 million in an IPO on Wednesday, October 31st 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and Cowen served as the underwriters for the IPO and Allen & Company and Baird were co-managers.

Twist Bioscience's top institutional investors include New York State Common Retirement Fund (0.82%), Allspring Global Investments Holdings LLC (0.14%), QRG Capital Management Inc. (0.05%) and Exchange Traded Concepts LLC (0.03%). Insiders that own company stock include Emily M Leproust, William Banyai, Patrick John Finn, Paula Green, Dennis Cho, Robert Chess, Robert F Werner, James M Thorburn, Jan Johannessen and Patrick Weiss.
View institutional ownership trends
.

Shares of TWST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Twist Bioscience investors own include Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), AUO (AUOTY), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR).

Company Calendar

Last Earnings
8/02/2024
Today
10/31/2024
Next Earnings (Confirmed)
11/18/2024
Fiscal Year End
9/30/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TWST
Fax
N/A
Employees
990
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$51.22
High Stock Price Target
$65.00
Low Stock Price Target
$35.00
Potential Upside/Downside
+26.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
9 Analysts

Profitability

Net Income
$-204,620,000.00
Pretax Margin
-74.48%

Debt

Sales & Book Value

Annual Sales
$295.21 million
Book Value
$10.86 per share

Miscellaneous

Free Float
56,289,000
Market Cap
$2.35 billion
Optionable
Optionable
Beta
1.77
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:TWST) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners